# Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial

> **NCT05083312** · PHASE3 · COMPLETED · sponsor: **Ellodi Pharmaceuticals, LP** · enrollment: 6 (actual)

## Conditions studied

- Eosinophilic Esophagitis

## Interventions

- **DRUG:** APT-1011
- **DRUG:** Placebo oral tablet

## Key facts

- **NCT ID:** NCT05083312
- **Lead sponsor:** Ellodi Pharmaceuticals, LP
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-30
- **Primary completion:** 2022-09-05
- **Final completion:** 2022-09-05
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05083312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05083312, "Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05083312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*